REPLIMUNE GROUP INC. - COMMON STOCK

Interim Results from the ARTACUS Clinical Trial of RP1 Monotherapy in Solid Organ and Hematopoietic Cell Transplant Recipients with Skin Cancers Presented During Oral Presentation at the American Association of Cancer Research (AACR) 2024 Annual Meeting

07 апр 2024 17:00:00 Источник Nasdaq GlobeNewswire

Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

04 апр 2024 08:00:00 Источник Nasdaq GlobeNewswire

Replimune Announces Appointment of Sushil Patel to CEO and Executive Leadership Transitions

26 мар 2024 07:30:00 Источник Nasdaq GlobeNewswire

Replimune to Present at the American Association for Cancer Research Annual Meeting 2024

06 мар 2024 08:00:00 Источник Nasdaq GlobeNewswire

Replimune to Present at Three Upcoming Investor Conferences

05 мар 2024 08:00:00 Источник Nasdaq GlobeNewswire

Replimune Reports Fiscal Third Quarter 2024 Financial Results and Provides Corporate Update

08 фев 2024 08:00:01 Источник Nasdaq GlobeNewswire

Replimune to Present at the 42nd Annual J.P. Morgan Healthcare Conference

28 дек 2023 08:00:00 Источник Nasdaq GlobeNewswire

Replimune Shares Initial Primary Analysis Results from CERPASS Clinical Trial in Advanced Cutaneous Squamous Cell Carcinoma and Presents New Data from IGNYTE Clinical Trial of RP1 in Anti-PD1 Failed Melanoma and Non-Melanoma Skin Cancers

05 дек 2023 07:00:00 Источник Nasdaq GlobeNewswire

Replimune Presents Updated Data on RP2 in Uveal Melanoma during Plenary Session at the 20th International Congress of the Society for Melanoma Research

08 ноя 2023 09:10:00 Источник Nasdaq GlobeNewswire

Replimune Reports Fiscal Second Quarter 2024 Financial Results and Provides Corporate Update

07 ноя 2023 08:00:01 Источник Nasdaq GlobeNewswire

Replimune Presents Updated Interim Results from the ARTACUS Clinical Trial of RP1 Monotherapy in Solid Organ and Hematopoietic Cell Transplant Recipients with Skin Cancers During Oral Presentation at the 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)

03 ноя 2023 19:30:00 Источник Nasdaq GlobeNewswire

Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

19 сен 2023 16:01:00 Источник Nasdaq GlobeNewswire

Replimune Announces Appointment of Emily Hill as Chief Financial Officer

19 сен 2023 08:00:00 Источник Nasdaq GlobeNewswire

Replimune Reports Fiscal First Quarter 2024 Financial Results and Provides Corporate Update

03 авг 2023 08:00:01 Источник Nasdaq GlobeNewswire

Replimune to Present at Two Upcoming Investor Conferences

01 авг 2023 08:00:00 Источник Nasdaq GlobeNewswire

Replimune Announces Sander Slootweg will Depart from its Board of Directors

20 июл 2023 08:00:01 Источник Nasdaq GlobeNewswire

Replimune Presents Initial RP1 Data from the ARTACUS Clinical Trial at the 2023 American Transplant Congress (ATC) Meeting

06 июн 2023 10:00:00 Источник Nasdaq GlobeNewswire

Replimune Appoints Veleka R. Peeples-Dyer to its Board of Directors

05 июн 2023 08:00:00 Источник Nasdaq GlobeNewswire

Replimune Presents RP1 Data from the IGNYTE anti-PD1 Failed Melanoma Cohort and RP2 Data in Uveal Melanoma at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting

03 июн 2023 14:15:00 Источник Nasdaq GlobeNewswire

Replimune to Present at the Jefferies Global Healthcare Conference

01 июн 2023 16:01:00 Источник Nasdaq GlobeNewswire